ZA917957B - Delivery of therapeutic agents using modified antibody fragments. - Google Patents

Delivery of therapeutic agents using modified antibody fragments.

Info

Publication number
ZA917957B
ZA917957B ZA917957A ZA917957A ZA917957B ZA 917957 B ZA917957 B ZA 917957B ZA 917957 A ZA917957 A ZA 917957A ZA 917957 A ZA917957 A ZA 917957A ZA 917957 B ZA917957 B ZA 917957B
Authority
ZA
South Africa
Prior art keywords
delivery
therapeutic agents
antibody fragments
modified antibody
therapeutic agent
Prior art date
Application number
ZA917957A
Other languages
English (en)
Inventor
Thomas Stewart Beggs
Paul James Davis
Martine Elisa Verhoeyen
Original Assignee
Unilever Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Plc filed Critical Unilever Plc
Publication of ZA917957B publication Critical patent/ZA917957B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A61K47/6885—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy the conjugate or the polymer being a starburst, a dendrimer, a cascade
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/94—Involves covalent bonding to the substrate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ZA917957A 1990-10-05 1991-10-04 Delivery of therapeutic agents using modified antibody fragments. ZA917957B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909021671A GB9021671D0 (en) 1990-10-05 1990-10-05 Delivery of agents

Publications (1)

Publication Number Publication Date
ZA917957B true ZA917957B (en) 1993-04-05

Family

ID=10683281

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA917957A ZA917957B (en) 1990-10-05 1991-10-04 Delivery of therapeutic agents using modified antibody fragments.

Country Status (11)

Country Link
US (1) US5490988A (no)
EP (1) EP0479600B1 (no)
JP (1) JPH04264036A (no)
AT (1) ATE157011T1 (no)
AU (1) AU653170B2 (no)
CA (1) CA2052713C (no)
DE (1) DE69127334T2 (no)
ES (1) ES2106057T3 (no)
GB (1) GB9021671D0 (no)
IN (1) IN174511B (no)
ZA (1) ZA917957B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2289679B (en) * 1993-01-15 1997-02-05 Imp Cancer Res Tech Compounds comprising a target cell-specific portion and a portion which has DNA endonucleolytic activity, and uses thereof
GB9300686D0 (en) * 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting
US5486360A (en) * 1993-04-22 1996-01-23 St. Joseph Health Centre Method of treating tumour cells using catalase
EP0824019B1 (en) * 1996-08-13 2002-11-20 Quest International B.V. Inhibition or reduction of oral malodour
US6929936B1 (en) * 1997-07-18 2005-08-16 Danisco A/S Composition comprising an enzyme having galactose oxidase activity and use thereof
US5871714A (en) * 1997-10-16 1999-02-16 Pharmacal Biotechnologies, Inc. Compositions for controlling bacterial colonization
NL1009834C2 (nl) * 1998-08-10 2000-02-11 Stanislaus Laurens Johan Woute Antistoffen voor toepassing in de gerichte en tijdelijke behandeling van mens en dier.
AU3489700A (en) * 1999-02-12 2000-08-29 Pharmacal Biotechnologies, Llc Oral compositions and methods of production thereof
ATE292475T1 (de) * 1999-09-16 2005-04-15 Unilever Nv Abgabesystem für ein mittel gegen schuppen
AU2001257613A1 (en) * 2000-04-23 2001-11-12 Arizeke Pharmaceuticals, Inc. Compositions comprising carriers and transportable complexes
US20030166160A1 (en) * 2001-09-06 2003-09-04 Hawley Stephen B. Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands
CA2424730A1 (en) * 2000-10-02 2002-04-11 Arizeke Pharmaceuticals, Inc. Compositions and methods for the transport of biologically active agents across cellular barriers
US20040058865A1 (en) * 2001-11-26 2004-03-25 Danishefsky Samuel J Homing peptide multimers, their preparation and uses
US8481678B2 (en) 2009-03-30 2013-07-09 E I Du Pont De Nemours And Company Peptide-based tooth whitening reagents
USD628389S1 (en) 2009-12-23 2010-12-07 Colgate-Palmolive Company Tissue cleaner
USD628808S1 (en) 2009-12-23 2010-12-14 Colgate-Palmolive Company Toothbrush
KR20140114269A (ko) 2010-12-20 2014-09-26 이 아이 듀폰 디 네모아 앤드 캄파니 표적화된 과가수분해효소
CA2822422C (en) 2010-12-20 2021-02-02 E. I. Du Pont De Nemours And Company Enzymatic peracid generation for use in oral care products

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4657853A (en) * 1984-09-14 1987-04-14 E. I. Du Pont De Nemours And Company Immunoassays utilizing covalent conjugates of polymerized enzyme and antibody
JPH0641424B2 (ja) * 1984-11-06 1994-06-01 ライオン株式会社 う蝕予防剤
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
ES2054678T5 (es) * 1986-08-18 1997-09-16 Dow Chemical Co Conjugados estrella.
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4943525A (en) * 1987-11-02 1990-07-24 Bioventures, Inc. Simultaneous immunoassay for the determination of antigens and antibodies
ATE119198T1 (de) * 1988-04-16 1995-03-15 Celltech Ltd Verfahren zur herstellung von proteinen mittels rekombinanter dna.
SE461570B (sv) * 1988-06-06 1990-03-05 Rama Bio Link Ab Farmaceutiskt preparat och konjugat av en baktericid och en antikropp
EP0361908A3 (en) * 1988-09-28 1990-09-05 Ideon Corporation Combination enzyme immunotherapeutics
JP2919890B2 (ja) * 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
FR2643267A1 (fr) * 1989-02-23 1990-08-24 Centre Nat Rech Scient Compositions a proprietes cytolytiques specifiques vis-a-vis de cellules cibles appropriees et leurs applications
WO1991000112A1 (en) * 1989-06-30 1991-01-10 Brunswick Corporation Antibody-lactate oxidase conjugates
EP0449998A4 (en) * 1989-06-30 1992-01-15 Brunswick Corporation Antibody-oxidase conjugates with non-systemic substrates
WO1991005856A1 (en) * 1989-10-13 1991-05-02 Loyola University Of Chicago Chimeric monoclonal antibodies generated by trans-splicing
GB8927230D0 (en) * 1989-12-01 1990-01-31 Unilever Plc Reagents
AU642979B2 (en) * 1990-03-21 1993-11-04 Quest International B.V. Utilization and delivery of enzymes

Also Published As

Publication number Publication date
EP0479600A2 (en) 1992-04-08
AU8555291A (en) 1992-04-09
ES2106057T3 (es) 1997-11-01
ATE157011T1 (de) 1997-09-15
DE69127334D1 (de) 1997-09-25
EP0479600A3 (en) 1992-12-09
CA2052713C (en) 1999-03-23
JPH04264036A (ja) 1992-09-18
CA2052713A1 (en) 1992-04-06
IN174511B (no) 1994-12-31
GB9021671D0 (en) 1990-11-21
EP0479600B1 (en) 1997-08-20
DE69127334T2 (de) 1998-01-15
AU653170B2 (en) 1994-09-22
US5490988A (en) 1996-02-13

Similar Documents

Publication Publication Date Title
ZA917957B (en) Delivery of therapeutic agents using modified antibody fragments.
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
DK0662827T3 (da) Terapeutiske og diagnostiske fremgangsmåder og sammensætninger baseret på Notch-proteiner og nucleinsyrer
TR199802423T2 (xx) Konsantre antikor terkibi.
GR3030141T3 (en) Diphtheria toxin receptor-binding region.
DE69637642D1 (de) Und kombinierte zusammensetzungen und deren verwendung
NZ294743A (en) A formulation for administering transdermally a protein or polypeptide such as insulin
DE69130741T2 (de) Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4-rezeptorbindung
NO20001104D0 (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende slike samt terapeutiske anvendelser derav
ATE319745T1 (de) Verfahren zur herstellung von nicht-immunogenen proteinen
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
DE69434384D1 (de) Metalkomplexbildner
HK1014158A1 (en) Anti-fungal methods and materials
AU4391689A (en) Chelants possessing ortho ligating functionality and complexes thereof
IL129359A0 (en) Bi-aromatic compounds bound by a heteroethynylene radical and pharmaceutical and cosmetic compositions containing same
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
AU641736B2 (en) Delivery of agents
HK1032534A1 (en) L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
WO1999050289A3 (en) Transformation progression-related genes and their use